Literature DB >> 17174013

Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.

Masaki Wakamatsu1, Aiko Ishii, Shingo Iwata, Junko Sakagami, Yuriko Ukai, Mieko Ono, Daiji Kanbe, Shin-ichi Muramatsu, Kazuto Kobayashi, Takeshi Iwatsubo, Makoto Yoshimoto.   

Abstract

Parkinson's disease is characterized by loss of nigral dopaminergic neurons and presence of Lewy bodies, whose major component is alpha-synuclein. In the present study, we generated transgenic mice termed Syn130m that express truncated human alpha-synuclein (amino acid residue number: 1-130) in dopaminergic neurons. Notably, dopaminergic neurons were selectively diminished in the substantia nigra pars compacta of Syn130m, while transgenic mice that expressed comparable amount of full-length human alpha-synuclein did not develop such pathology. Therefore, the truncation of human alpha-synuclein seems to be primarily responsible for the loss of nigral dopaminergic neurons. The nigral pathology resulted in impairment of axon terminals in the striatum and concomitant decrease in striatal dopamine content. Behaviorally, spontaneous locomotor activities of Syn130m were reduced, but the abnormality was ameliorated by treatment with L-DOPA. The loss of nigral dopaminergic neurons was not progressive and seemed to occur during embryogenesis along with the onset of expression of the transgene. Our results indicate that truncated human alpha-synuclein is deleterious to the development and/or survival of nigral dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17174013     DOI: 10.1016/j.neurobiolaging.2006.11.017

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  57 in total

Review 1.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

Review 2.  Value of genetic models in understanding the cause and mechanisms of Parkinson's disease.

Authors:  Darren J Moore; Ted M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

3.  Exogenous α-Synuclein Monomers Alter Dopamine Metabolism in Murine Brain.

Authors:  Adriana Wawer; Ilona Joniec-Maciejak; Anna Sznejder-Pachołek; Joanna Schwenkgrub; Agnieszka Ciesielska; Dagmara Mirowska-Guzel
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

4.  Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.

Authors:  Zachary A Sorrentino; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Kevin H Strang; Jason Caldwell; Benoit I Giasson
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

5.  Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2012-10-24       Impact factor: 6.167

6.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

Review 7.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

8.  Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption.

Authors:  Youngshin Lim; Vicky M Kehm; Chi Li; John Q Trojanowski; Virginia M-Y Lee
Journal:  Exp Neurol       Date:  2009-10-13       Impact factor: 5.330

9.  Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons.

Authors:  João Paulo L Daher; Mingyao Ying; Rebecca Banerjee; Rebecca S McDonald; Myriam Dumas Hahn; Lichuan Yang; M Flint Beal; Bobby Thomas; Valina L Dawson; Ted M Dawson; Darren J Moore
Journal:  Mol Neurodegener       Date:  2009-07-24       Impact factor: 14.195

10.  Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

Authors:  Dora Games; Peter Seubert; Edward Rockenstein; Christina Patrick; Margarita Trejo; Kiren Ubhi; Benjamin Ettle; Majid Ghassemiam; Robin Barbour; Dale Schenk; Silke Nuber; Eliezer Masliah
Journal:  Am J Pathol       Date:  2013-01-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.